Can-Fite BioPharma price target raised to $12 from $8.25 at Alliance Global Partners

Alliance Global Partners raised the firm’s price target on Can-Fite BioPharma to $12 from $8.25 and keeps a Buy rating on the shares. The firm is anticipating a solid second half of 2023-2024 as Piclidenoson and Namodenoson advance in late stage trials. Last month, Can-Fite BioPharma announced that they had received feedback from the FDA on the registrational plan of Piclidenoson for the treatment of moderate to severe plaque psoriasis. The company is alsoplanning on submitting an IND application for Namodenoson in a pancreatic cancer indication, the firm notes.